OTCPK:IDGX.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Integrated Diagnostics Holdings

Executive Summary

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. More Details


Snowflake Analysis

Excellent balance sheet and good value.

Share Price & News

How has Integrated Diagnostics Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IDGX.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.5%

IDGX.F

1.6%

US Healthcare

1.0%

US Market


1 Year Return

-19.7%

IDGX.F

15.9%

US Healthcare

13.6%

US Market

Return vs Industry: IDGX.F underperformed the US Healthcare industry which returned 15.9% over the past year.

Return vs Market: IDGX.F underperformed the US Market which returned 13.6% over the past year.


Shareholder returns

IDGX.FIndustryMarket
7 Day8.5%1.6%1.0%
30 Day17.6%-4.4%-0.4%
90 Day-2.5%1.1%8.9%
1 Year-19.7%-19.7%17.4%15.9%16.2%13.6%
3 Yearn/a29.1%23.4%40.2%30.8%
5 Yearn/a52.8%42.1%89.6%68.2%

Price Volatility Vs. Market

How volatile is Integrated Diagnostics Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Integrated Diagnostics Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IDGX.F ($3.95) is trading below our estimate of fair value ($10.46)

Significantly Below Fair Value: IDGX.F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IDGX.F is good value based on its PE Ratio (19.1x) compared to the US Healthcare industry average (22.4x).

PE vs Market: IDGX.F is poor value based on its PE Ratio (19.1x) compared to the US market (18.4x).


Price to Earnings Growth Ratio

PEG Ratio: IDGX.F is good value based on its PEG Ratio (1x)


Price to Book Ratio

PB vs Industry: IDGX.F is overvalued based on its PB Ratio (3.7x) compared to the US Healthcare industry average (2.9x).


Next Steps

Future Growth

How is Integrated Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

19.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDGX.F's forecast earnings growth (19.8% per year) is above the savings rate (2.2%).

Earnings vs Market: IDGX.F's earnings (19.8% per year) are forecast to grow slower than the US market (23.2% per year).

High Growth Earnings: IDGX.F's earnings are forecast to grow, but not significantly.

Revenue vs Market: IDGX.F's revenue (14.9% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: IDGX.F's revenue (14.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IDGX.F's Return on Equity is forecast to be high in 3 years time (29%)


Next Steps

Past Performance

How has Integrated Diagnostics Holdings performed over the past 5 years?

24.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IDGX.F has high quality earnings.

Growing Profit Margin: IDGX.F's current net profit margins (22%) are lower than last year (24.1%).


Past Earnings Growth Analysis

Earnings Trend: IDGX.F's earnings have grown significantly by 24.7% per year over the past 5 years.

Accelerating Growth: IDGX.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: IDGX.F had negative earnings growth (-8.6%) over the past year, making it difficult to compare to the Healthcare industry average (31.1%).


Return on Equity

High ROE: IDGX.F's Return on Equity (18.2%) is considered low.


Next Steps

Financial Health

How is Integrated Diagnostics Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IDGX.F's short term assets (EGP1.1B) exceed its short term liabilities (EGP674.8M).

Long Term Liabilities: IDGX.F's short term assets (EGP1.1B) exceed its long term liabilities (EGP607.7M).


Debt to Equity History and Analysis

Debt Level: IDGX.F's debt to equity ratio (4.1%) is considered satisfactory.

Reducing Debt: IDGX.F's debt to equity ratio has increased from 0% to 4.1% over the past 5 years.

Debt Coverage: IDGX.F's debt is well covered by operating cash flow (595.9%).

Interest Coverage: IDGX.F's interest payments on its debt are well covered by EBIT (66x coverage).


Balance Sheet


Next Steps

Dividend

What is Integrated Diagnostics Holdings's current dividend yield, its reliability and sustainability?

4.95%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: IDGX.F's dividend (4.95%) is higher than the bottom 25% of dividend payers in the US market (1.66%).

High Dividend: IDGX.F's dividend (4.95%) is in the top 25% of dividend payers in the US market (4.68%)


Stability and Growth of Payments

Stable Dividend: IDGX.F has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: IDGX.F's dividend payments have increased, but the company has only paid a dividend for 4 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (97.2%), IDGX.F's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: IDGX.F's dividends in 3 years are forecast to be covered by earnings (83.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average board tenure


CEO

Hend El Sherbini (51 yo)

8.67yrs

Tenure

ج.م9,475,201

Compensation

Prof. Dr. Hend El Sherbini has been Group Chief Executive Officer of Integrated Diagnostics Holdings plc since 2012 and as its Executive Director since December 23, 2014. Prof. Dr. El Sherbini serves as th ...


CEO Compensation Analysis

Compensation vs Market: Hend's total compensation ($USD601.91K) is below average for companies of similar size in the US market ($USD2.02M).

Compensation vs Earnings: Hend's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Hend El Sherbini
Group CEO & Executive Director8.67yrsج.م9.48m25.5%
EGP 144.4m
Anthony St. John Bletso
Independent Non-Executive Chairman5.67yrsج.م1.23mno data
Richard Phillips
Non-Executive Director5.75yrsno datano data
James Nolan
Independent Non-Executive Director5.42yrsج.م981.45kno data
Hussein Choucri
Independent Non-Executive Director5.67yrsج.م462.08kno data
Dan Olsson
Independent Non-Executive Director5.67yrsج.م899.66kno data

5.7yrs

Average Tenure

57.5yo

Average Age

Experienced Board: IDGX.F's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Integrated Diagnostics Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Integrated Diagnostics Holdings plc
  • Ticker: IDGX.F
  • Exchange: OTCPK
  • Founded: 1979
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$566.250m
  • Shares outstanding: 150.00m
  • Website: https://www.idhcorp.com

Number of Employees


Location

  • Integrated Diagnostics Holdings plc
  • 12 Castle Street
  • Saint Helier
  • JE2 3RT
  • Jersey

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IDHCLSE (London Stock Exchange)YesOrdinary SharesGBUSDMay 2015
IDHCLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBUSDMay 2015
IDGX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2015

Biography

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 1,400 diagnostic test services, including immunology, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 06:10
End of Day Share Price2020/09/14 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.